Mark G. Currie
InvestorVenture Partner at Iaso Ventures · Executive at Cyclerion Therapeutics · Board director at Sea Pharmaceuticals · Executive at Ironwood Pharmaceuticals
Boston, Massachusetts, United States
Find your path to Mark
66 people in our graph share verified history with Mark — schools, employers, funds. One of them is your warm intro.
John McKearnunlockedMark: together at Searle (1990–1999)
×7Mark: together at Antag Therapeutics
×2Mark: together at University of South Alabama
Mark: together at Cyclerion Therapeutics
About
Biopharma leader and pharmacologist, former President and CSO and scientific founder of Cyclerion Therapeutics and R&D leader at Ironwood. Primary inventor of linaclotide (Linzess), with numerous board and advisory roles.
Executive at Cyclerion Therapeutics
Intro paths
→
In turn, Mark can intro founders to Cyclerion Therapeutics's investors below.
Board director at Sea Pharmaceuticals
Intro paths
→
In turn, Mark can intro founders to Sea Pharmaceuticals's investors below.
Sea Pharmaceuticals's investors · 1
Co-founders at Sea Pharmaceuticals
BC
Benjamin CravattManager
Executive at Ironwood Pharmaceuticals
Intro paths
→
In turn, Mark can intro founders to Ironwood Pharmaceuticals's investors below.
Ironwood Pharmaceuticals's investors · 6
F-Prime CapitalCambridge · $3M – $10M checks · since 2016Maverick VenturesSan Francisco · $3M – $10M checks · since 2016Mountain Group CapitalNashville · since 2016Polaris PartnersBoston · $500K – $5M checks · since 2016Ridgeback CapitalMiami · since 2016VenrockPalo Alto · $500K – $10M checks · since 2016
Co-founders at Ironwood Pharmaceuticals
PM
PETER M. HECHTExecutive Officer, Director
Experience
- Prudentia SciencesChair SABcurrent2025 — presentGreater Boston
- Scaffold TherapeuticsChair SABcurrent2025 — presentBoston, Massachusetts, United States
- Iaso VenturesVenture Partnercurrent2024 — presentGreater Boston
- Antag TherapeuticsBoard Membercurrent2023 — presentCopenhagen, Capital Region of Denmark, Denmark
- Ironwood PharmaceuticalsDirector Board Of Directorscurrent2019 — present
- Ironwood PharmaceuticalsSenior Vice President2008 — 2019
- Sea PharmaceuticalsMember Board Of Directorscurrent2021 — present
- CyclerionChair of Scientific Advisory Board2021 — 2025
- CyclerionPresident2019 — 2021
- Science ExchangeDirector Board Of Directors2020 — 2025Palo Alto, California, United States
- MicrobiaChief Science Officer2002 — 2008Greater Boston Area
- Sepracor IncVice President of Discovery1999 — 2002Greater Boston Area
- SearleSenior Director Discovery Pharmacology1990 — 1999Greater St. Louis Area
Deals · 1
Sea PharmaceuticalsBoard seat
via Iaso Ventures · filed May 2026 · $1.7M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Iaso Ventures
Anil S. Jina
Executive in Residence at Iaso Ventures
Brian O'Connor
Executive Officer at Iaso Ventures
Chandra Ramanathan
Advisor, Biotech at Iaso Ventures
John Reynders
Chief Data Scientist & Venture Partner at Iaso Ventures
Lambertus Johannes Hermanus Becht
Executive Officer at Iaso Ventures
Maurizio Fava
Advisor, Clinical R&D at Iaso Ventures
Michael Fenn
Venture Partner at Iaso Ventures
Noah J. Richmond
Advisor, Legal & IP at Iaso Ventures
Frequently asked questions
- Who is Mark G. Currie?
- Biopharma leader and pharmacologist, former President and CSO and scientific founder of Cyclerion Therapeutics and R&D leader at Ironwood. Primary inventor of linaclotide (Linzess), with numerous board and advisory roles.
- Where does Mark G. Currie work?
- Mark G. Currie is Venture Partner at Iaso Ventures and Executive at Cyclerion Therapeutics and Board director at Sea Pharmaceuticals and Executive at Ironwood Pharmaceuticals.
- What boards does Mark G. Currie sit on?
- Mark G. Currie holds tracked board seats at Sea Pharmaceuticals.
- Where did Mark G. Currie go to school?
- Mark G. Currie studied at Wake Forest University School of Medicine (Doctor of Philosophy - PhD, Cell Biology and Anatomy); University of South Alabama (Bachelor of Science - BS, Biology); University of South Alabama (Bachelor of Science - BS, Cell/Cellular Biology and Histology).
Same school
Also attended Wake Forest University School of Medicine16
Paulina HillPartner at Sanofi VenturesDavid AdairCo-Founder and Managing Director at Solas BioVenturesSamantha PulliamCEO and Chief Medical Officer at Axena HealthRobert GlanzmanExecutive Officer at CleneVolker KnappertzExecutive Vice President of Research & Development at Noema PharmaCHRISTOPHER TOOMBSExecutive Officer at Proniras
+ 10 more
Also attended University of South Alabama15
CindiInvestor at TFX CapitalAditya JInvestment Analyst at Titan CapitalAnahit MnatsakanyanAnalyst, Life Sciences & Project Manager at SmartGateVCSam TillinghastBoard Observer at Houston Angel NetworkPete HayesPartner at Blu Venture InvestorsWill ShermanCTO, Co-Founder at Reditus Space
+ 9 more
Shared employers
Also worked at Prudentia Sciences4
Also worked at Antag Therapeutics12
Iqbal MuftiOperating Partner - Portfolio Business Development at SR One Capital ManagementLene GerlachVenture Partner at Hadean VenturesEmmanuelle CoutanceauPartner at Novo HoldingsJørgen Søberg PetersenSenior Partner at Novo HoldingsJeroen BakkerPartner at Novo HoldingsThomas NeedhamDirector, Head of the Biopharma Practice at Broadview Ventures
+ 6 more
Also worked at Ironwood Pharmaceuticals14
Peter ColabuonoManaging Director at Decheng CapitalChristina IsacsonPartner at Lightstone VenturesJoe Cook JrManaging Director at Mountain Group CapitalJeffrey SilberExecutive Officer at Vedanta BiosciencesTHOMAS A. MCCOURTExecutive Officer at Ironwood PharmaceuticalsJohn CrowleyExecutive Officer at Merus
+ 8 more
